• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer

    1/2/25 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care
    Get the next $NXGL alert in real time by email

    LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant.

    Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operations and finance. Joe brings many decades of public company and financial experience that will be invaluable during this critical juncture in our company history."

    Mr. Levy continued, "I would like to thank Adam Drapczuk for his invaluable contributions to NEXGEL's progress and success. We wish him good luck as he builds his own consulting business through Achieving Consulting Excellence, LLC, and are pleased that we can still rely on him moving forward."

    Mr. McGuire has over 30 years of financial and public company experience, having served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. He was a key member of the team that successfully guided a biotechnology company through its IPO, resulting in its listing on the NYSE in July 2022. In these roles, Mr. McGuire's responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. He began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Mr. McGuire received a Bachelor of Science in accounting from the University of Notre Dame. Mr. McGuire has consulted with NEXGEL since September 2, 2024, and will serve on the executive management team to lead the Company's finance functions.

    Mr. McGuire, newly appointed Chief Financial Officer of NEXGEL, commented, "It is an exciting time to be part of NEXGEL. Adam Levy and his team have executed consistently and exceeded the markets expectations. I look forward to working with him, Adam Drapczuk and the rest of the team going forward."

    About NEXGEL, Inc.

    NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

    Forward-Looking Statement

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs, such as "will," "should," "would," "may," and "could," are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2023, including but not limited to the discussion under "Risk Factors" therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

    Investor Contacts:

    Valter Pinto, Managing Director

    KCSA Strategic Communications

    212.896.1254

    [email protected]



    Primary Logo

    Get the next $NXGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXGL

    DatePrice TargetRatingAnalyst
    2/25/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $NXGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Levy Adam R. bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 1% to 333,196 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:14 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Zeldis Jerome B bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 4% to 106,664 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:12 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Stein John Nachum gifted 4,000 shares and bought $9,999 worth of shares (3,636 units at $2.75), decreasing direct ownership by 0.08% to 471,456 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:08 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    SEC Filings

    See more
    • NexGel Inc filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NEXGEL, INC. (0001468929) (Filer)

      6/4/25 4:30:51 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by NexGel Inc

      10-Q - NEXGEL, INC. (0001468929) (Filer)

      5/13/25 5:00:29 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NexGel Inc filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEXGEL, INC. (0001468929) (Filer)

      5/13/25 4:18:17 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NXGL
    Financials

    Live finance-specific insights

    See more

    $NXGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NXGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Maxim Group initiated coverage on NexGel with a new price target

      Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00

      2/25/22 9:17:01 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Reports First Quarter 2025 Financial Results

      First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the period ending March 31, 2025. First Quarter 2025 Financial Highlights: Net Revenue was $2.81 million, compared to $1.27 million in Q1 2024 and $3.04 million in Q4 2024.Gross Profit

      5/13/25 4:05:00 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL to Report First Quarter 2025 Financial Results on May 13th

      Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p.m. ET on the same day. First Quarter 2025 Financial Results Conference CallDate: May 13, 2025Time: 4:30 P.M. ETLive Call: 1-800-343-4849 (U.S. Toll Free) or 1-203-518-9848 (Internatio

      5/9/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023 Over 100% full year and fourth quarter revenue growth year-over-year for third consecutive year Company issues revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year LANGHORNE, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record

      3/24/25 4:05:00 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2nd

      LANGHORNE, Pa., May 21, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will participate in the 6th Annual CEO Networking Event hosted by Semco Capital in Chicago on Monday, June 2, 2025 from 1-9 p.m. CT. During the event Mr. Levy will participate in a fireside chat hosted by Scott Weis of Semco Capital. The Annual CEO Networking Event hosted by Semco Capital brings together a consortium of leading microcap companies with unique business m

      5/21/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Reports First Quarter 2025 Financial Results

      First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the period ending March 31, 2025. First Quarter 2025 Financial Highlights: Net Revenue was $2.81 million, compared to $1.27 million in Q1 2024 and $3.04 million in Q4 2024.Gross Profit

      5/13/25 4:05:00 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL to Report First Quarter 2025 Financial Results on May 13th

      Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p.m. ET on the same day. First Quarter 2025 Financial Results Conference CallDate: May 13, 2025Time: 4:30 P.M. ETLive Call: 1-800-343-4849 (U.S. Toll Free) or 1-203-518-9848 (Internatio

      5/9/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Levy Adam R. sold $2,220 worth of shares (1,000 units at $2.22), decreasing direct ownership by 0.27% to 368,284 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      6/2/25 8:00:07 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Levy Adam R. sold $2,575 worth of shares (1,000 units at $2.58), decreasing direct ownership by 0.27% to 369,284 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      5/20/25 8:00:04 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Henry Scott Robert sold $8,062 worth of shares (3,000 units at $2.69), decreasing direct ownership by 2% to 132,053 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      5/13/25 8:00:04 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Leadership Updates

    Live Leadership Updates

    See more
    • NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer

      LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati

      1/2/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Appoints Kip Crecca to its Scientific Advisory Board

      LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e

      10/4/24 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Appoints Scott Henry, CFA to Board of Directors and Audit Committee

      LANGHORNE, Pa., Jan. 17, 2023 /PRNewswire/ -- NEXGEL, Inc. (NASDAQ:NXGL, NXGLW))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company's Board of Directors (the "Board"), effective immediately. Mr. Henry will also serve as a member of the Board's Audit Committee. "Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, Chief Executive Officer of NEXGEL. "Additionally, his vast network within the investment comm

      1/17/23 7:30:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care